Teleflex announced that long‑time board member Stuart Randle will serve as interim President and Chief Executive Officer, following the departure of former CEO Liam Kelly, who stepped down as Chairman, President and CEO. Dr. Stephen Klasko, the company’s Lead Director, has been named Chairman of the Board to guide the transition.
Randle brings more than 35 years of experience in the medical‑device industry, having held executive roles at Act Medical, GI Dynamics and Optobionics. In his new role he will oversee the integration of the BIOTRONIK Vascular Intervention unit, manage the divestiture of the Acute Care, Interventional Urology and OEM businesses, and focus on executing the RemainCo strategy until a permanent CEO is selected.
Teleflex has completed a major portfolio transformation that will leave the company focused on critical‑care and high‑acuity hospital markets. The divestitures of the Acute Care, Interventional Urology and OEM businesses, combined with the acquisition of BIOTRONIK’s vascular intervention business for approximately $791 million, are intended to streamline operations and accelerate growth in the interventional cardiology and peripheral vascular segments.
The company lowered its preliminary full‑year 2025 revenue guidance to $3.27 billion–$3.278 billion, down from the prior guidance of $3.305 billion–$3.320 billion. Management cited softer demand for intra‑aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes in certain portfolio segments as the primary reasons for the revision.
Dr. Klasko said, “With the announced sale of our Acute Care, Interventional Urology and OEM businesses, Teleflex is entering its next phase as a more focused, higher‑growth organization, and we are confident that Stuart will lead effectively during this period.” Randle added, “I am pleased to serve as Teleflex’s interim CEO and work with the leadership team to advance our transformation, drive growth and create value for our stakeholders.”
The divestitures reduce complexity and free capital that can be deployed into high‑margin, high‑growth areas, while the integration of BIOTRONIK is expected to generate synergies and broaden Teleflex’s product portfolio in the vascular space. However, the company’s near‑term outlook remains cautious, reflecting the demand softness and order delays that prompted the revenue guidance cut.
Overall, the leadership transition and revised revenue outlook signal a period of strategic realignment and operational focus. Investors and stakeholders will be watching how effectively the interim leadership executes the RemainCo strategy and whether the integration of BIOTRONIK delivers the anticipated growth and margin improvements.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.